Navigation Links
Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
Date:5/10/2011

erapy were randomized to receive certolizumab pegol (400mg at weeks 0, 2 and 4 followed by 200mg or 400mg every two weeks*) plus MTX, or placebo together with MTX for 24 weeks. The primary outcome measure was ACR 20 response at week 24.

At week 24, significantly more patients in the certolizumab pegol treatment groups reported improvements greater than or equal to MCID in all six PROs (pain, fatigue, patient's global assessment of disease (PtGA), physical function by HAQ, and HRQOL by SF-36 physical and mental component summary scores). The beneficial effects of certolizumab pegol were similar between the 200mg and 400mg dose levels with no significant difference between treatment groups in any PROs.

Furthermore, at week 24, 63% of certolizumab pegol 200mg treated patients reported clinically meaningful improvements in greater than or equal to 1 PRO compared with 13% in placebo groups, and approximately 23% of all certolizumab pegol treated patients reported clinically meaningful improvements in all six PROs compared with 3% in placebo groups.

The NNT for reported changes greater than or equal to MCID in all six PROs was approximately five patients, and these results showed the highest correlation between pain, PtGA and fatigue. The NNT for reported changes greater than or equal to MCID in up to five PROs was 2-3.

Improvements greater than or equal to MCID in pain were investigated to predict outcomes at week 24. Those patients achieving pain MCID by week 12 were more likely to have better outcomes than those who did not achieve MCID at week 12. Additionally, a comparison of week 6 and 12 responders, showed approximately 27% of patients who reported improvements greater than or equal to MCID in pain at week 6 achieved low disease activity (LDA) at week 24, compared with 16% of week 12 responders.

* In the EU, the approved maintenance dose regimen is 200mg every two weeks. In the US, the approved maintenance dose regimen is 200mg e
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
2. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
3. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
4. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
5. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
6. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
7. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
8. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
9. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
10. New Subanalyses of the RE-LY Trial Showed Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scores and Types of Non-Valvular Atrial Fibrillation
11. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... SALT LAKE CITY , Aug. 28, 2014 /PRNewswire-iReach/ ... in 2000 by service academy graduates, has published a ... its concentrated, three-day Leadership Excellence Course . In ... the  Leadership Excellence Course to Albuquerque , ... Tucson . Photo - http://photos.prnewswire.com/prnh/20140828/140814 ...
(Date:8/28/2014)... , August 28, 2014 ... "DNA diagnostics Market (products, applications, techniques, end users ... Growth and Forecast, 2013 - 2020," indicates that ... billion by 2020 registering a CAGR of 9.8% ... accurate diagnosis and cost effectiveness over alternative diagnostic ...
(Date:8/28/2014)... , Aug. 28, 2014   Venaxis, Inc. ... focused on obtaining FDA clearance for and commercializing its ... test for aiding in identifying children, adolescent, and young ... low risk for appendicitis, today announced it will present ... 16 th Annual Global Investment Conference being held ...
Breaking Medicine Technology:Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3
... Model of Diabetes with Haptoglobin 2-2 Genotype Show, ... Transport, MONTVALE, N.J., March 31 Synvista,Therapeutics, ... a study of diabetic mice,with the Haptoglobin 2-2 ... Haptoglobin (Hp)-Hemoglobin (Hb) complex may result in a ...
... is now enrolling ... patients, ... announced today the start of a Phase III clinical trial,studying LY450139, an ... LY450139 is being tested,to see if it can slow the progression associated ...
Cached Medicine Technology:Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 2Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 3Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 4Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 2Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 3Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 4Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 5Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 6
(Date:8/28/2014)... did the earliest birds take wing? Did they fall from ... Or did they run along the ground and pump their ... million years in the past, but a new University of ... birds have an innate ability to maneuver in midair, a ... rather than fall from a perch. , The study looked ...
(Date:8/28/2014)... NJ Top Docs Presents Dr. Christophe Oliveira ... Top Doc, Dr. Christophe Oliveira, has just announced ... for the department of transportation. Dr. Oliveira has ... all drug testing for commercial drivers. , Having ... disorders including disk herniations, spinal stenosis, muscle sprains/strains, ...
(Date:8/28/2014)... (BRONX, NY) Researchers from Albert Einstein College of ... a potential antibody therapy for Sudan ebolavirus (SUDV), one of ... the Zaire ebolavirus (EBOV), is now devastating West Africa. First ... (most recently in 2012) that have killed more than ... ACS Chemical Biology . , Between 30 and 90 ...
(Date:8/28/2014)... In 2012, The Ben & Catherine Ivy Foundation ... brain cancer research projects at the Translational Genomics ... officially received the final regulatory approval from University ... for the trial can begin. , In the ... Trial," TGen and its clinical partners will lead ...
(Date:8/28/2014)... A herbal preparation prescribed by a Chinese herbal ... in life-threatening heart changes, prompting a team of ... appropriate patient education by practitioners who prescribe complementary ... , the journal of the Australasian College for ... and Dr Nicky Dobos from the Intensive Care ...
Breaking Medicine News(10 mins):Health News:Flapping baby birds give clues to origin of flight 2Health News:Flapping baby birds give clues to origin of flight 3Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 2Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 3Health News:Drug shows promise against Sudan strain of Ebola in mice 2Health News:TGen receives approval for patient enrollment in brain cancer clinical trial 2Health News:Deadly remedy: Warning issued about Chinese herbal medicine 2
... Bulgaria’s Agriculture Minister Nihat Kabil has revealed that ... bird flu. The bird was however not infected ... dangerous H5 virus. The dead swan was found ... was unable to say whether avian flu had ...
... expected in poultry during the course of 2006, according to ... take place // among human beings on a large scale, ... Governments have however been called upon to be prepared ... have been called upon to improve their surveillance where the ...
... end up losing as many as over 200 doctors, over the ... abortion. // The Catholic doctors who are from Queensland are of ... be deprived of his powers when it comes to deciding upon ... ,The AMA on the other hand is calling for ...
... meeting with Boston Scientific to talk about the repairs in ... held in 2001 with Schering-Plough // about problems with its ... to make any amendments. This provoked the FDA to withhold ... solve this problem Raul E. Cesan, the company's president and ...
... of the Teratology Society published a paper in the journal ... ,In this paper they said that overweight and ... develop medical problems at birth. ,This paper talked ... obese mothers. , It is stated that they ...
... closely monitored surveillance for patients with colon and rectal ... recurrence // compared to less aggressive strategy which is ... found that an intensified follow up of patients in ... diagnosis of cancer recurrence which could help in treatment ...
Cached Medicine News:
For the quantitative determination of alkaline phosphatase in human serum....
... of low density lipoprotein cholesterol ... Liquid stable, ready-to-use reagent. Selective ... measurement. Excellent correlation with established ... substances. Available with Calibrator: Trucal ...
Storage temperature: 2 - 8C, linearity: 0 - 25 mg/dL, expected value: male: 3.5 - 7.0 mg/dL and female: 2.5 - 6.0 mg/dL. Available with calibrator and number of test 500....
The assay kit is for determination of uric acid in serum or urine. Wavelength: 600 nm. Linear range: up to 80 mg/dL....
Medicine Products: